Amlodipine Besylate Tablet
Product Images NDC 51655-869

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 51655-869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 869 52 Rev A 08 23)

Label (51655 869 52   Rev A 08 23)
Label for Amlodipine Besylate Tablets, USP 10 mg oral tablets. The package contains 30 tablets and is labeled for prescription use only. Storage instructions advise keeping the product at 20°-25°C and protecting from light and moisture. The product is labeled by Northwind Health Company, LLC.*
FDA Label Image

Image (Dc48db65 Ee80 4852 A3aa A23ec74f4416 01)

Image (Dc48db65 Ee80 4852 A3aa A23ec74f4416 01)
Chemical structure diagram of amlodipine besylate, showing the arrangement of atoms including carbon, hydrogen, oxygen, nitrogen, chlorine, and sulfur in the molecule.*
FDA Label Image

Image2 (Dc48db65 Ee80 4852 A3aa A23ec74f4416 02)

Image2 (Dc48db65 Ee80 4852 A3aa A23ec74f4416 02)
A line graph depicting event rates over 24 months comparing Amlodipine and placebo groups. The x-axis represents time in months, and the y-axis shows event rates. Two curves are labeled: Placebo and Amlodipine, with Amlodipine showing a lower event rate. A text box displays statistical values including P-value=0.003, Hazard Ratio=0.691, and 95% Confidence Interval (0.54, 0.88). The number at risk is indicated below the x-axis at various time points.*
FDA Label Image

Image3 (Dc48db65 Ee80 4852 A3aa A23ec74f4416 03)

Image3 (Dc48db65 Ee80 4852 A3aa A23ec74f4416 03)
A hazard ratio forest plot comparing amlodipine versus placebo across various patient subgroups, including overall population, age groups (<65 and >=65), gender, baseline sitting systolic blood pressure, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strata. The plot shows hazard ratios with 95% confidence intervals to illustrate treatment effect variation among subgroups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.